Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 23 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

39%

9 trials in Phase 3/4

Results Transparency

65%

15 of 23 completed trials have results

Key Signals

15 with results

Enrollment Performance

Analytics

Phase 3

9(40.9%)

Phase 1

9(40.9%)

Phase 2

4(18.2%)

22Total

Phase 3(9)

Phase 1(9)

Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials

NCT02123134Phase 3Completed

Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age

Role: lead

NCT02035267Phase 3Completed

Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat

Role: lead

NCT02163902Phase 3Completed

Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

Role: lead

NCT02159729Phase 2Completed

Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

Role: lead

NCT02438813Completed

Condition of Submental Fullness and Treatment Outcomes Registry

Role: lead

NCT01462786Phase 1Completed

To Evaluate the Safety, Tolerability and to Compare the Pharmacokinetic Profile of ATX-101

Role: lead

NCT01426373Phase 3Completed

Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area

Role: lead

NCT00608842Phase 2Completed

Phase 2 Study for the Treatment of Superficial Lipomas

Role: lead

NCT00422188Phase 1Completed

Deoxycholic Acid Injection for the Treatment of Superficial Lipomas

Role: lead

NCT02007434Phase 3Completed

Patient Experience Study of Deoxycholic Acid Injection

Role: lead

NCT00618722Phase 1Completed

Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat

Role: lead

NCT01305577Phase 3Completed

Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat

Role: lead

NCT00618618Phase 2Completed

Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat

Role: lead

NCT01032889Phase 2Completed

Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study

Role: lead

NCT01546142Phase 3Completed

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

Role: lead

NCT01542034Phase 3Completed

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

Role: lead

NCT01294644Phase 3Completed

Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat

Role: lead

NCT00618709Phase 1Completed

Dose-Escalation Safety and Pharmacokinetic Study of ATX-101

Role: lead

NCT01706679Phase 1Completed

Evaluation of the Effect of ATX-101 on QT/QTc Intervals

Role: lead

NCT01632917Phase 1Completed

Open-Label Pharmacokinetic Study of Final Formulations of ATX-101

Role: lead